Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Oric Pharmaceuticals Inc., 3 years.
Oric Pharmaceuticals Inc.
Director
Prelude Therapeutics Incorporated
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −646 | $431.94 | $279,033 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −40 | $425.08 | $17,003 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −420 | $426.86 | $179,281 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −80 | $427.85 | $34,228 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −160 | $429.00 | $68,640 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −40 | $429.58 | $17,183 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −120 | $430.90 | $51,708 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −116 | $432.56 | $50,177 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −160 | $434.20 | $69,472 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −80 | $435.32 | $34,826 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −80 | $436.69 | $34,935 |
| Mar 6, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −40 | $437.65 | $17,506 |
| Mar 4, 2026 | Madrigal Pharmaceuticals Inc. | Grant or award | +5,215 | — | — |
| Mar 2, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,183 | $427.21 | $505,389 |
| Dec 2, 2025 | Madrigal Pharmaceuticals Inc. | Option exercise | +4,173 | $251.63 | $1,050,052 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.